Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04237792 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 128
- Enrollment target
NCT04237792 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 128 participants.
The verdict
NCT04237792, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 128 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects ≥1 month to \<17 years of age undergoing MRI scans in the US and Japan.
Interventions
- DRUG propofol
- DRUG dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04237792
The ClinicalTrials.gov registry entry for NCT04237792 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which propofol is the first listed.
NCT04237792 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04237792 about?
NCT04237792 is a clinical study titled "Safety and Efficacy of Dexmedetomidine (DEX) for Sedation of Subjects ≥1 Month to <17 Years Undergoing MRI Scans". This is a randomized, double-blind, dose-ranging study of the efficacy and safety of dexmedetomidine (DEX) when used with propofol as needed, for procedural sedation of pediatric subjects ≥1 month to \<17 years of age undergoing MRI scans in the US and Japan.
What is the current status of trial NCT04237792?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 128 participants. The study started on 2020-02-18. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT04237792?
The interventions under investigation include: propofol (DRUG), dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT04237792?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.